Decoding the plasma proteome: Advancing precision medicine in cardiovascular health

The plasma proteome offers a dynamic window into human physiology, enabling biomarker discovery, target prioritization, and drug repurposing for cardiovascular disease. Advances in high-throughput platforms, protein quantitative trait loci mapping, and machine learning reveal pleiotropic proteins and candidate causal targets, but translation requires rigorous safeguards. We propose a rigorous, tiered pipeline: discovery, mandatory orthogonal confirmation (targeted mass spectrometry or independent immunoassay), genetic prioritization with colocalization and sensitivity analyses, tissue-resolved functional validation, and prospective clinical evaluation with regulatory qualification. Integration with multi-omics, diverse cohorts, and electronic health record-embedded implementation studies, using HL7 Fast Healthcare Interoperability Resources and the Observational Medical Outcomes Partnership Common Data Model, can accelerate reproducible, equitable development of precision cardiovascular therapeutics.